Such targeted molecules have shown efficacy in a preclinical model of RA in which transgenic mice that express human CES1 under the CD68 promotor were generated to allow human CES1 expression in mononuclear myeloid cells [32]. The gene discussed is CES1; the disease is rheumatoid arthritis.